NASDAQ:MACK - Merrimack Pharmaceuticals, Inc.
$6.00
 $-0.01
-0.17%
4:00PM EDT
2019-04-18
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MACK     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 65   199. 07   233. 87  
42 stocks rank:  3. 70 K 1. 43 K 1. 06 K
# analyst opinions:  1. 00   14. 48   14. 09  
mean recommendation:  3. 50   2. 09   2. 01  

quick ratio:  4. 82   5. 29   1. 92  
current ratio:  5. 14   5. 64   2. 40  

ex-dividend date:     2017-05-29
target price low:  4. 00   84. 50   115. 74  
target price avg:  4. 00   110. 73   137. 39  
target price high:  4. 00   136. 41   157. 80  
1-yr high:  9. 67   114. 11   138. 85  
last close:  6. 60   87. 56   116. 78  
50-day avg:  6. 34   95. 43   123. 53  
200-day avg:  5. 27   94. 13   121. 20  
1-yr low:  3. 75   72. 67   98. 41  
volume:  74. 15 K 2. 43 M 4. 85 M
50-day avg volume:  64. 21 K 2. 72 M 4. 97 M
200-day avg volume:  88. 54 K 2. 90 M 4. 58 M

1-day return:  -0. 17 % -0. 40 % 0. 07 %
this week return:  1. 87 % -5. 72 % -4. 11 %
12-wk return:  16. 05 % 1. 78 % -0. 04 %
52-wk return:  -32. 24 % 10. 81 % 14. 09 %

enterprise value (EV):  20. 45 M 51. 19 B 117. 96 B
market cap:  80. 05 M 43. 00 B 104. 52 B
EBITDA:  -60. 20 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 34   4. 34   13. 27  
total debt:  14. 87 M 12. 22 B 16. 66 B
debt/equity:  25. 29   46. 86   89. 46  
net income (common):  -60. 77 M 2. 20 B 4. 21 B

shares outstanding:  13. 34 M 570. 91 M 1. 24 B
shares:  8. 93 M 571. 02 M 1. 23 B
shares short:  306. 62 K 9. 93 M 16. 79 M
shares short prior month:  362. 82 K 9. 96 M 16. 58 M
short ratio:  7. 57   5. 31   3. 30  
short % of float:  2. 74 % 5. 81 % 2. 61 %
total cash/share:  5. 34   11. 13   9. 30  
total cash:  71. 28 M 6. 70 B 7. 10 B
free cash flow:  -41. 96 M 3. 58 B 4. 74 B
operating cash flow:  -65. 59 M 4. 14 B 6. 32 B

book value:  4. 41   12. 76   26. 84  
price/book:  1. 36   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -43. 83 % --- ---
1-yr mean volatility:  -0. 04 % 0. 03 % 0. 04 %

1-yr EPS:  -3. 04   2. 39   4. 08  
forward EPS:  -1. 78   3. 97   7. 14  
P/E:  -1. 98   13. 59   22. 83  
forward P/E:  -3. 31   -20. 05   14. 49  
PE/G:  0. 08   -1. 46   1. 68  
growth:  -25. 30 % 126. 81 % 29. 29 %
earnings high:  -0. 00   1. 02   1. 63  
earnings avg:  -0. 00   0. 76   1. 51  
earnings low:  -0. 00   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -39. 03 % -2. 80 % 5. 29 %
return on equity:  -78. 36 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  0. 75   1. 24   0. 93  
sharpe (1yr):  -0. 14   0. 29   0. 60  

held % insiders:  4. 09 % 6. 38 % 3. 38 %
held % institutions:  57. 26 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : MACK
.        + 0 =             0 :: INITIAL WEIGHT
.   + 35.323 =        35.323 :: spline projection addition
.    x 1.432 =        50.583 :: industry recommendation factor
.    x 0.996 =        50.386 :: return on assets factor
.    x 0.992 =        49.991 :: return on equity factor
.    x 2.912 =       145.589 :: current ratio factor
.    x 1.123 =       163.547 :: quick ratio factor
.    x 1.064 =       174.014 :: short ratio factor
.    x 2.014 =       350.397 :: price-to-book factor
.    x 1.241 =       434.774 :: debt-to-equity factor
.    x 1.129 =       490.751 :: 5-day avg > 200-day avg
.    x 1.204 =       590.703 :: 50-day avg > 200-day avg
.    x 2.143 =      1266.112 :: P/E weight
.    x 1.892 =      2394.981 :: PE/G factor
.    x 1.516 =      3630.634 :: beta factor
.    x 0.136 =        494.82 :: sharpe factor
.    x 0.942 =       466.252 :: target low factor
.    x 0.898 =       418.539 :: target mean factor
.    x 0.942 =       394.375 :: target high factor
.    x 1.312 =       517.281 :: industry 2-weeks return factor
.      x 0.6 =       310.477 :: overall "drift" factor
.    x 0.998 =       309.898 :: largest single-day jump factor
.    x 0.089 =        27.719 :: low price factor
.      x 1.0 =        27.715 :: factor hist industry gain for week 15
.   cubeRoot =         3.026 :: reduced to standardize
.   - 18.776 =         0.653 :: add/subtract for performance
.                      0.653 :: FINAL WEIGHT for NASDAQ:MACK


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org